Carmel Wroth
Carmel Wroth is a senior health editor for NPR's Science Desk, where she guides digital strategy for the health team and conceives and edits digital-first, enterprise stories and packages.
Formerly, she founded and managed Side Effects Public Media, a public radio collaborative covering public health in the Midwest. Wroth also served as an editor at Yoga Journal for five years.
-
The highly contagious delta variant of the coronavirus is spreading fast and driving new cases and hospitalizations. Here's what you need to know to keep yourself and your kids from getting sick. -
As the delta variant takes over in the U.S., new, localized outbreaks are emerging. Those surges are likely driven by pockets of dangerously low vaccination rates.
-
Can I get a massage? Travel with my unvaccinated kids? Eat indoors at a restaurant? Hit the gym? Experts weigh in with advice on 16 frequently asked post-vaccination questions. -
Many favorite holiday traditions could be treacherous this year because of the coronavirus. Here's how experts view the risks — and some creative, safer alternatives to keep up a festive mood. -
The President's diagnosis calls for contact tracing on a massive scale. Luckily, not everyone President Trump saw this week with is a high risk exposure. Here's who is. -
As schools weigh the risks of reopening, many are making plans to lower the risks of coronavirus transmission. Here's how to vet your school's proposals. -
A new color-coded map, backed by a coalition of top scientists, provides a way of comparing outbreak severity across communities, down to the county level. -
The weather is warming up and public spaces are starting to reopen. How do you decide what's safe to do? We have guidance to help you compare and evaluate the risks. -
New estimates say the U.S. needs to triple its testing. But how much testing does each state need? Here's how states compare to each other, and to targets experts say they should hit. -
The preliminary results showed that hospitalized patients who received remdesivir recovered 31% faster. Dr. Anthony Fauci hailed the findings as "quite good news."
